Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MIRM NASDAQ:PTGX NASDAQ:SYRE NASDAQ:VIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMIRMMirum Pharmaceuticals$93.48+1.1%$97.29$45.17▼$114.99$5.64B0.51.12 million shs585,273 shsPTGXProtagonist Therapeutics$97.38-5.3%$101.33$49.38▼$107.84$6.61B1.85501,511 shs887,396 shsSYRESpyre Therapeutics$73.65-6.2%$66.62$13.93▼$79.54$6.82B3.05955,091 shs1.46 million shsVIRVir Biotechnology$8.65-5.5%$9.49$4.16▼$11.66$1.54B1.651.58 million shs1.33 million shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMIRMMirum Pharmaceuticals+0.50%-7.14%-12.59%+7.17%+107.33%PTGXProtagonist Therapeutics+7.74%+2.37%+3.61%+11.62%+99.48%SYRESpyre Therapeutics+6.75%+8.83%+10.52%+95.47%+375.06%VIRVir Biotechnology+4.33%-4.19%-8.59%-4.19%+73.30%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMIRMMirum Pharmaceuticals$93.48+1.1%$97.29$45.17▼$114.99$5.64B0.51.12 million shs585,273 shsPTGXProtagonist Therapeutics$97.38-5.3%$101.33$49.38▼$107.84$6.61B1.85501,511 shs887,396 shsSYRESpyre Therapeutics$73.65-6.2%$66.62$13.93▼$79.54$6.82B3.05955,091 shs1.46 million shsVIRVir Biotechnology$8.65-5.5%$9.49$4.16▼$11.66$1.54B1.651.58 million shs1.33 million shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMIRMMirum Pharmaceuticals+0.50%-7.14%-12.59%+7.17%+107.33%PTGXProtagonist Therapeutics+7.74%+2.37%+3.61%+11.62%+99.48%SYRESpyre Therapeutics+6.75%+8.83%+10.52%+95.47%+375.06%VIRVir Biotechnology+4.33%-4.19%-8.59%-4.19%+73.30%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMIRMMirum Pharmaceuticals 2.93Moderate Buy$137.6447.24% UpsidePTGXProtagonist Therapeutics 2.88Moderate Buy$115.2118.31% UpsideSYRESpyre Therapeutics 3.00Buy$91.3324.01% UpsideVIRVir Biotechnology 2.89Moderate Buy$20.38135.55% UpsideCurrent Analyst Ratings BreakdownLatest VIR, PTGX, SYRE, and MIRM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2026SYRESpyre Therapeutics Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$102.00 ➝ $115.006/3/2026VIRVir Biotechnology Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$20.00 ➝ $21.006/2/2026MIRMMirum Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Outperform ➝ Buy$145.006/1/2026MIRMMirum Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform5/22/2026MIRMMirum Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/21/2026PTGXProtagonist Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$135.005/21/2026PTGXProtagonist Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$135.005/19/2026MIRMMirum Pharmaceuticals Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$145.005/19/2026MIRMMirum Pharmaceuticals Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$145.005/15/2026PTGXProtagonist Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)5/12/2026SYRESpyre Therapeutics Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$102.00(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMIRMMirum Pharmaceuticals$569.61M10.01$0.05 per share1,801.42$6.12 per share15.27PTGXProtagonist Therapeutics$74.06M84.56N/AN/A$9.83 per share9.91SYRESpyre TherapeuticsN/AN/AN/AN/A$7.21 per shareN/AVIRVir Biotechnology$64.69M22.55N/AN/A$5.50 per share1.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMIRMMirum Pharmaceuticals-$23.36M-$13.61N/A406.43N/A-140.24%-11.28%-3.84%7/30/2026 (Estimated)PTGXProtagonist Therapeutics-$130.15M-$1.81N/AN/AN/A-154.88%-17.76%-16.47%8/5/2026 (Estimated)SYRESpyre Therapeutics-$155.20M-$2.08N/AN/AN/AN/A-42.88%-27.76%8/4/2026 (Estimated)VIRVir Biotechnology-$437.99M-$3.13N/AN/AN/A-638.88%-53.31%-41.76%8/5/2026 (Estimated)Latest VIR, PTGX, SYRE, and MIRM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2026Q1 2026MIRMMirum Pharmaceuticals-$0.75-$13.43-$12.68-$13.43$148.21 million$159.88 million5/6/2026Q1 2026VIRVir Biotechnology-$0.01-$0.85-$0.84-$0.85$55.49 million($0.03) million5/5/2026Q1 2026PTGXProtagonist Therapeutics-$0.5004$0.05+$0.5504$0.05$11.70 million$56.37 million5/5/2026Q1 2026SYRESpyre Therapeutics-$0.66-$0.74-$0.08-$0.74$70.87 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/ASYRESpyre TherapeuticsN/AN/AN/AN/AN/AVIRVir BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMIRMMirum Pharmaceuticals1.282.091.99PTGXProtagonist TherapeuticsN/A17.7617.76SYRESpyre TherapeuticsN/A8.978.97VIRVir BiotechnologyN/A7.117.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMIRMMirum PharmaceuticalsN/APTGXProtagonist Therapeutics98.63%SYRESpyre Therapeutics80.39%VIRVir Biotechnology65.32%Insider OwnershipCompanyInsider OwnershipMIRMMirum Pharmaceuticals8.32%PTGXProtagonist Therapeutics5.19%SYRESpyre Therapeutics15.69%VIRVir Biotechnology2.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMIRMMirum Pharmaceuticals14060.98 million55.91 millionOptionablePTGXProtagonist Therapeutics12064.31 million60.97 millionOptionableSYRESpyre Therapeutics7386.84 million73.22 millionOptionableVIRVir Biotechnology580168.65 million163.76 millionOptionableVIR, PTGX, SYRE, and MIRM HeadlinesRecent News About These CompaniesVir Biotechnology (NASDAQ:VIR) Given New $21.00 Price Target at Leerink PartnersJune 4 at 3:38 AM | americanbankingnews.comVir Biotechnology (NASDAQ:VIR) Price Target Raised to $21.00June 3 at 10:40 AM | marketbeat.comInsider Selling: Vir Biotechnology (NASDAQ:VIR) Director Sells 3,200 Shares of StockJune 3 at 6:29 AM | insidertrades.comVir Biotechnology, Inc. (VIR) Presents at EASL Congress 2026 - SlideshowMay 30, 2026 | seekingalpha.comVir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Rating of "Moderate Buy" by AnalystsMay 28, 2026 | marketbeat.comSF Biotech Boss Slashes Labs, Bets Big On Cancer In High-Stakes Vir MakeoverMay 27, 2026 | hoodline.comHUBS Group AG Purchases 203,203 Shares of Vir Biotechnology, Inc. $VIRMay 27, 2026 | marketbeat.comHow SOLSTICE Phase 2 HDV Data at Vir Biotechnology (VIR) Has Changed Its Investment StoryMay 25, 2026 | finance.yahoo.comWhy a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock RallyMay 23, 2026 | aol.comAVir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL ...May 19, 2026 | finance.yahoo.comVir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 MillionMay 19, 2026 | finance.yahoo.comVir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026May 18, 2026 | businesswire.comVir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million SharesMay 17, 2026 | finance.yahoo.comVir Biotechnology: Trading Near Cash Value With A Huge Revenue OpportunityMay 16, 2026 | seekingalpha.comHow Marianne De Backer saved Vir after flu drug failureMay 15, 2026 | bizjournals.comVanguard Group Inc. Reduces Stock Position in Vir Biotechnology, Inc. $VIRMay 15, 2026 | marketbeat.comVir jumps after Phase 1 data for Sanofi-partnered cancer drug technologyMay 14, 2026 | msn.comVir Biotechnology, Inc. (VIR) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 12, 2026 | seekingalpha.comQ2 EPS Estimates for Vir Biotechnology Cut by HC WainwrightMay 12, 2026 | marketbeat.comResults: Vir Biotechnology, Inc. Delivered A Surprise Loss And Now Analysts Have New ForecastsMay 11, 2026 | finance.yahoo.comA Look At Vir Biotechnology (VIR) Valuation After The Astellas Partnership And Pipeline ProgressMay 10, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 2026Before the Moon Base Gets Built, These 4 Companies WinBy Thomas Hughes | May 11, 2026IonQ Just Posted a Breakout Quarter—But 1 Problem RemainsBy Nathan Reiff | May 7, 2026Is Co-Diagnostics National Security’s Next Diagnostic Pick?By Jeffrey Neal Johnson | May 28, 2026Mirum Pharma: A Rare Disease Growth Story to WatchBy Chris Markoch | May 20, 2026VIR, PTGX, SYRE, and MIRM Company DescriptionsMirum Pharmaceuticals NASDAQ:MIRM$93.48 +0.99 (+1.07%) Closing price 04:00 PM EasternExtended Trading$92.76 -0.73 (-0.78%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.Protagonist Therapeutics NASDAQ:PTGX$97.38 -5.41 (-5.26%) Closing price 04:00 PM EasternExtended Trading$98.71 +1.33 (+1.36%) As of 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.Spyre Therapeutics NASDAQ:SYRE$73.65 -4.83 (-6.15%) Closing price 04:00 PM EasternExtended Trading$73.50 -0.15 (-0.20%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.Vir Biotechnology NASDAQ:VIR$8.65 -0.50 (-5.46%) Closing price 04:00 PM EasternExtended Trading$8.67 +0.02 (+0.23%) As of 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
